Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 1.00 |
| ▸ | CYSLTR2 | Q9NS75 | 16/20 | 0.74 |
| ▸ | CYSLTR1 | Q9Y271 | 16/20 | 0.74 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.74 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | PGR | P06401 | 1/20 | 0.74 |
| ▸ | HTR1A | P08908 | 1/20 | 0.74 |
| ▸ | AR | P10275 | 1/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.74 |
| ▸ | DRD1 | P21728 | 1/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.74 |
| ▸ | PDE4A | P27815 | 1/20 | 0.74 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.74 |
| ▸ | DRD3 | P35462 | 1/20 | 0.74 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.74 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15547055 | 0.87 | RUVBL1 (0.76) | RUVBL1CYSLTR2CYSLTR1NR1H4ABCC4 | |
| SCHEMBL18870151 | 0.86 | RUVBL1 (0.75) | RUVBL1CYSLTR2CYSLTR1NR1H4ABCC4 | |
| Pranlukast SCHEMBL18058592 | 0.85 | CYSLTR2 (1.00) | RUVBL1CYSLTR2CYSLTR1NR1H4ABCC4 | |
| Pranlukast SCHEMBL29349894 | 0.85 | CYSLTR2 (1.00) | RUVBL1CYSLTR2CYSLTR1NR1H4ABCC4 | |
| Pranlukast SCHEMBL29749274 | 0.84 | CYSLTR2 (1.00) | RUVBL1CYSLTR2CYSLTR1NR1H4ABCC4 | |
| SCHEMBL6956086 | 0.80 | RUVBL1 (0.67) | RUVBL1CYSLTR2CYSLTR1NR1H4ABCC4 | |
| SCHEMBL6962842 | 0.80 | RUVBL1 (0.66) | RUVBL1CYSLTR2CYSLTR1NR1H4ABCC4 | |
| SCHEMBL8115074 | 0.75 | RUVBL1 (0.60) | RUVBL1CYSLTR2CYSLTR1NR1H4ABCC4 | |
| SCHEMBL6950678 | 0.74 | RUVBL1 (0.59) | RUVBL1CYSLTR2CYSLTR1NR1H4ABCC4 | |
| SCHEMBL7897057 | 0.74 | RUVBL1 (0.59) | RUVBL1CYSLTR2CYSLTR1NR1H4ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12633 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6436924-B1 | — | — | None | — | — | US | claimed |
| EP-4676956-A2 | ANTI-STEM CELL FACTOR (SCF) AND ANTI-THYMIC STROMAL LYMPHOPOIETIN (TSLP) ANTIBODIES AND BISPECIFIC CONSTRUCTS | Celldex Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | claimed |
| EP-4678659-A1 | MONOCLONAL ANTIBODY PREPARATION TARGETING TSLP | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2026-01-14 | — | — | EP | claimed |
| US-20260000646-A1 | Inhibition of Oral Microbe Biofilms | THE UNIVERSITY OF TOLEDO (US) | 2026-01-01 | — | — | US | claimed |
| WO-2025264860-A2 | METHODS OF TREATING POST-COVID AIRWAY DISEASE | YALE UNIVERSITY (US) | 2025-12-26 | — | — | WO | claimed |
| WO-2025244529-A1 | DOSING REGIMEN OF AN EGFR BINDING AND/OR COMPLEMENT ACTIVATING ANTIBODY | MERUS N.V. (NL) | 2025-11-27 | — | — | WO | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2025122933-A1 | METHODS FOR THE DETECTION AND TREATMENT OF HEMATOLOGIC MALIGNANCY ASSOCIATED HYPERINFLAMMATION | CHILDRENS HOPSITAL MEDICAL CENTER (US) | 2025-06-12 | — | — | WO | claimed |
| WO-2025122021-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF), THROUGH TARGETING OF S100A9 AND CORRESPONDING DIMER PARTNER AND RECEPTORS | I3S - INSTITUTO DE INVESTIGAÇÃO E INOVAÇÃO EM SAÚDE, ASSOCIAÇÃO (PT) | 2025-06-12 | — | — | WO | claimed |
| WO-2025110687-A1 | PHARMACEUTICAL COMPOSITION COMPRISING BEPOTASTINE AND PRANLUKAST | 대원제약주식회사 | 2025-05-30 | — | — | WO | claimed |
| WO-1999052553-A1 | METHODS AND COMPOSITIONS USING CETIRIZINE IN COMBINATION WITH LEUKOTRIENE INHIBITORS FOR TREATING CONDITIONS RESPONSIVE TO LEUKOTRIENE INHIBITION | SEPRACOR INC. (US) | 1999-10-21 | — | — | WO | claimed |
| WO-1999052554-A1 | METHODS AND COMPOSITIONS USING TERFENADINE METABOLITES IN COMBINATION WITH LEUKOTRIENE INHIBITORS | SEPRACOR INC. (US) | 1999-10-21 | — | — | WO | claimed |
| WO-1999052555-A1 | METHODS AND COMPOSITIONS USING NORASTEMIZOLE IN COMBINATION WITH LEUKOTRIENE INHIBITORS | SEPRACOR INC. (US) | 1999-10-21 | — | — | WO | claimed |
| WO-1999044592-A1 | ANTI-ASTHMA THERAPY | ALZA CORPORATION (US) | 1999-09-10 | — | — | WO | claimed |
| WO-1999032125-A1 | COMPOSITION FOR TREATING RESPIRATORY AND SKIN DISEASES, COMPRISING AT LEAST ONE LEUKOTRIENE ANTAGONIST AND AT LEAST ONE ANTIHISTAMINE | SCHERING CORPORATION (US) | 1999-07-01 | — | — | WO | claimed |
| CN-1210465-A | Methods of treatment and pharmaceutical compositions | MERCK & CO INC (US) | 1999-03-10 | — | — | CN | claimed |
| US-5876760-A | Granules containing pranlukast, process for producing the granules, and method of improving adhesiveness of pranlukast | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-03-02 | — | — | US | claimed |
| WO-1998041193-A1 | PREPARATION OF POWDER AGGLOMERATES | SCHERING CORPORATION (US) | 1998-09-24 | — | — | WO | claimed |
| EP-0834314-A1 | GRANULES CONTAINING PRANLUKAST, PROCESS FOR PRODUCING THE GRANULES, AND METHOD OF LOWERING COHESIVENESS OF PRANLUKAST | ONO PHARMACEUTICAL CO., LTD. (JP) | 1998-04-08 | — | — | EP | claimed |
| WO-1997028797-A1 | METHOD OF TREATMENT AND PHARMACEUTICAL COMPOSION | MERCK & CO., INC. (US) | 1997-08-14 | — | — | WO | claimed |